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Fine-Mapping of Vitiligo Susceptibility Loci
on Chromosomes 7 and 9 and Interactions
with NLRP1 (NALP1)
Ying Jin1, Sheri L. Riccardi1, Katherine Gowan1, Pamela R. Fain1,2 and Richard A. Spritz1
Generalized vitiligo is the most common pigmentation disorder, the result of autoimmune loss of melanocytes
from the skin and hair, with a high frequency of other autoimmune diseases in vitiligo patients and their
relatives. We previously reported the linkage signals on chromosomes 1, 7, and 17 in Caucasian families with
generalized vitiligo and associated autoimmune diseases and identified the risk loci of chromosomes 17 and 1
as NLRP1 (NALP1) and FOXD3, respectively. Here, we describe fine-scale genetic association analyses in two
independent series of Caucasian multiplex families, refining localization of the chromosome 7 locus and a locus
on chromosome 9. Three susceptibility signals, represented by single-nucleotide polymorphisms (SNPs)
rs6960920 in 7p13, rs734930 in 7q11, and rs4744411 in 9q22, were significantly associated with vitiligo and other
autoimmune diseases. We also detected significant three-way interaction effects of chromosome 7 SNP
rs6960920, chromosome 9 SNP rs4744411, and NLRP1 SNP rs6502867 on both the vitiligo phenotype and an
expanded autoimmune disease phenotype, and significant three-way interaction effects of both chromosome
7 SNPs and NLRP1 SNP rs6502867 on the vitiligo phenotype. These support the validity of the chromosomes
7 and 9 linkage/association signals and underscore the utility of gene–gene interaction analysis in characterizing
the genetic effects of candidate association signals.
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INTRODUCTION
Generalized vitiligo is an acquired, non-contagious disorder,
in which progressive, patchy loss of pigmentation from the
skin, overlying hair, and oral mucosa results from auto-
immune loss of melanocytes from the involved areas
(Nordlund et al., 2006). The most common pigmentation
disorder, vitiligo, occurs in about 0.4% of European
Caucasians (Howitz et al., 1977), with similar prevalence in
other populations (Spritz, 2007, 2008). First-degree relatives
of affected patients have B6 to 7% risk of vitiligo, and
concordance in monozygotic twins is 23% (Alkhateeb et al.,
2003). About 25–30% of generalized vitiligo patients manifest
at least one other autoimmune disease, particularly auto-
immune thyroid disease (Graves’ disease and autoimmune
hypothyroidism), rheumatoid arthritis, psoriasis, adult-onset
autoimmune diabetes mellitus, pernicious anemia, Addison’s
disease, and systemic lupus erythematosus; these same
disorders also occur in increased frequency in patients’
first-degree relatives (Alkhateeb et al., 2003; Laberge et al.,
2005). Thus, this complex of associated autoimmune diseases
likely results from the interaction of multiple disease
susceptibility variants (Majumder et al., 1993; Nath et al.,
1994; Sun et al., 2006), some predisposing to a general
autoimmune diathesis and others to specific autoimmune
diseases.
A number of candidate genes have been reported as
associated with generalized vitiligo, including loci in the
major histocompatibility complex, ACE, CAT, CTLA4,
COMT, ESR, GCH1, MBL, PTPN22, VDR, and others (Spritz,
2007, 2008). Most of these studies reported only marginally
significant associations, often with no correction for multiple
testing, and several were not replicated by subsequent studies
(Spritz, 2007, 2008).
We previously reported significant linkage (logarithm of
the odds (LODs) X3.0) of generalized vitiligo to loci on
chromosomes 1, 7, 8, and 17 and suggestive linkage (LODs
X2.0) to loci on chromosomes 9, 13, 19, and 22 in an
analysis of 102 multiplex generalized vitiligo families. The
linkage signals on chromosomes 1, 7, and 17 derived
principally from the subset of 51 families segregating
both vitiligo and additional vitiligo-associated autoimmune
diseases, whereas the linkage signal on chromosome 8 was
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derived principally from the subset of families segregating
only vitiligo (Spritz et al., 2004). Subsequently, we identified
the chromosome 17 vitiligo-autoimmunity susceptibility
locus as NLRP1 (NACHT leucine-rich-repeat protein) (Jin
et al., 2007), encoding NALP1, a key regulator of the innate
immune system, and the linkage signal on chromosome 1
derived primarily from a single large family (Alkhateeb et al.,
2002), in which generalized vitiligo co-segregated with a
promoter variant in FOXD3 (Alkhateeb et al., 2005).
The purpose of the current study was to refine localization
of these putative vitiligo-autoimmune disease susceptibility
loci. We first carried out improved genetic linkage analysis,
increasing linkage support for the chromosomes 7 and 9 loci,
whereas greatly reducing support for loci on chromosomes
13, 19, and 22. We then carried out fine-scale genetic
association analyses through the chromosomes 7 and 9
linkage regions in the aforementioned 51 families that
segregated both vitiligo and additional associated autoim-
mune diseases, detecting apparent association for 17 single-
nucleotide polymorphisms (SNPs) from the chromosome 7
linkage region and 8 SNPs from the chromosome 9 linkage
region. We then re-tested these SNPs in an independent
series of 63 vitiligo-autoimmune disease families, with a joint
analysis showing significant associations on both chromo-
somes after correction for multiple testing. We next investi-
gated potential genetic interactions among these variants and
with the known vitiligo susceptibility variants in NLRP1,
detecting significant interactions that underscore the poly-
genic, complex nature of vitiligo and associated autoimmune
diseases.
RESULTS
Genetic linkage analysis
We first reassessed the evidence for genetic linkage, filtering
the previous microsatellite data (Spritz et al., 2004) using
an improved error-checking routine implemented in
Merlin 1.1.2 (Abecasis et al., 2002), and then re-analyzing
linkage in the total 102 multiplex vitiligo families and
the subset of 51 families that also segregated other
autoimmune diseases using Allegro 1.2c (Gudbjartsson
et al., 2000). With these enhanced analyses, the maximum
multipoint LOD for chromosome 7 increased to 4.31
(P¼6.0710–6) for the total 102 families and 4.01
(P¼1.5210–6) for the 51 vitiligo-autoimmune disease
families; the LOD maximum was located at 89.4 cM and
the 1-LOD interval spanned B33.3 cM in 7q21. Similarly, a
locus on chromosome 9, which previously showed only
suggestive evidence for linkage in the total 102 vitiligo
families (Spritz et al., 2004), now yielded a maximum
multipoint LOD score of 2.37 (P¼2.2410–4) for the total
102 families and 3.18 (P¼ 6.3510–5) for the 51 vitiligo-
autoimmune disease families; the LOD maximum was
at 88.1 cM and the 1-LOD interval spanned B17.7 cM in
9q12-q22. In contrast, support for putative vitiligo suscept-
ibility loci on chromosomes 8, 13, 19, and 22 was
reduced substantially, below the threshold for suggestive
linkage (LOD 1.9); accordingly, these three signals were not
pursued further.
Family-based association studies
To refine localization of the chromosome 7 and 9 vitiligo-
autoimmunity susceptibility loci, we next carried out family-
based association analyses of high-density SNPs genotyped
through the 1-LOD linkage intervals. We genotyped 333
members of the aforementioned 51 vitiligo-autoimmune
disease families for 867 SNPs spanning the chromosome 7
linkage region and 304 SNPs spanning the chromosome 9
linkage region, respectively, capturing 38.6 and 27.2% of the
common variation (minor allele frequency 40.1, r240.5) in
these regions (NCBI Genome Build 35). Two SNPs from
chromosome 7 and four from chromosome 9 deviated from
the Hardy–Weinberg equilibrium (Po0.005) in unrelated
founders and were excluded from further analyses. We used
both the pedigree disequilibrium test (PDT) (Martin et al.,
2000) and the family-based association test (FBAT) (Horvath
et al., 2004) to assess the remaining markers for association
with both vitiligo and with an expanded autoimmune disease
phenotype that included family members with either vitiligo
or any of the principal vitiligo-associated autoimmune
diseases (Alkhateeb et al., 2003; Laberge et al., 2005; see
Materials and Methods) as ‘‘affected.’’ SNPs showing
nominal evidence of association (Po0.05) with vitiligo
and/or the expanded autoimmunity phenotype, of which
vitiligo is a subset, in both PDT and FBAT analyses (Figure 1,
Tables S1, S2) were then genotyped in 323 family members
from an independent series of 63 vitiligo-autoimmune
disease families. Altogether, we tested 17 SNPs from the
chromosome 7 linkage region and 8 SNPs from the
chromosome 9 linkage region for association in the second
series of 63 families, corresponding to 14 independent tests
after allowing for marker–marker linkage disequilibrium (LD,
Figure 2).
Of the 17 SNPs from the chromosome 7 linkage region
showing both PDT and FBAT association with the vitiligo
phenotype and/or with the expanded autoimmune disease
phenotype in the first family series, four (rs6960920,
rs2331071, rs2240100, and rs734930) SNPs also showed
nominally significant association (Po0.05) in PDT analyses
of both phenotypes and nominally significant or marginal
association in FBAT analyses of the vitiligo phenotype in the
second family series (Table 1, Table S1). The PDT P-values of
these four SNPs in the combined sample of 114 families
(series 1 and series 2 together) were significant for the vitiligo
phenotype after the Bonferroni correction for the 14
independent tests of chromosome 7 and 9 SNPs (nominal
P-valueo0.00357). SNP rs734930 showed the strongest
evidence for association, with significant corrected P-values
in PDT, FBAT, and conditional logistic regression analysis
(CLRA) of the vitiligo phenotype (odds ratio (OR)¼ 1.85), and
PDT analysis of the expanded autoimmune disease pheno-
type (OR¼ 1.55). The other three chromosome 7 SNPs
(rs6960920, rs2331071, and rs2240100) cluster in a block
of strong LD (Figure 2).
To evaluate the relative effects of these four SNPs, we
carried out stepwise CLRA of the case–pseudocontrol data set
(Cordell and Clayton, 2002) derived from the combined 114
families. The effects of individual SNPs in the three-SNP
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cluster were indistinguishable by these analyses, and no
haplotype explained the disease associations better than any
individual SNPs (data not shown). However, including
rs734930 significantly improved the fit of models that
included any one of the three other SNPs; conversely,
including any one of rs6960920, rs2331071, and rs2240100
significantly improved the fit of models that included
rs734930 (Table 2). Thus, at least two independent chromo-
some 7 variants appear to contribute to genetic associ-
ation with the vitiligo phenotype (Table 2), one tagged by
rs734930 and the other tagged by the three-SNP cluster
rs6960920–rs2331071–rs2240100.
Of the eight chromosome 9 SNPs showing both PDT and
FBAT association with the vitiligo phenotype and/or the
expanded autoimmune disease phenotype in the first
family series, four (rs1350564, rs4744369, rs391784, and
rs4744411) showed nominally significant or marginal asso-
ciation in FBAT analyses of both phenotypes and nominally
significant association in PDT analyses of the expanded
autoimmune disease phenotype in the second family series
(Table 3, Table S2). The FBAT P-values of these four SNPs
in the combined sample of 114 families were significant
for both phenotypes after the Bonferroni correction for the
14 independent tests. SNP rs4744411 showed the stron-
gest evidence for association with both phenotypes
(OR¼2.03 for the vitiligo phenotype and OR¼ 2.05 for the
expanded autoimmune disease phenotype).
As all four of these chromosome 9 SNPs are clustered in a
block of strong LD (Figure 2), we again used CLRA to
evaluate the relative effects of individual SNPs. Including
rs2584806 (vitiligo phenotype) or rs391784 (vitiligo pheno-
type and expanded autoimmune disease phenotype) signifi-
cantly improved the fit of models that included rs4744369,
but including rs4744369 did not significantly improve the fit
of models that included either rs2584806 or rs391784
(Table 4). The individual effects of rs2584806, rs391784,
and rs4744411 were indistinguishable by these analyses, and
no SNP haplotype explained the disease associations better
than did any individual SNPs (data not shown). Thus, the
association of rs4744369 with disease is secondary to LD
with the other SNPs.
Genetic interaction analyses
We next explored potential genetic interactions among the
two independent vitiligo susceptibility signals we detected on
chromosome 7p and 7q (tagged by rs6960920 and rs734930,
respectively), the signal on 9q (tagged by rs4744411), and the
susceptibility variants of NLRP1 on chromosome 17p that we
identified previously (tagged by rs6502867 and rs4790797)
(Jin et al., 2007). We carried out CLRA in the combined
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Figure 1. Association of generalized vitiligo and associated autoimmune diseases with chromosome 7 and 9 linkage region SNPs. (a) Minus log10 (P-values)
from the pedigree disequilibrium test (PDT) (Martin et al., 2000) and the family-based association test (FBAT) (Horvath et al., 2004) for the vitiligo phenotype
for 867 SNPs genotyped across the chromosome 7 linkage region in the first 51 multiplex families with vitiligo and other autoimmune diseases (series 1).
(b) Minus log10 (P-values) from PDT and FBAT for the expanded autoimmune disease phenotype for 867 SNPs genotyped across the chromosome 7
linkage region in these 51 families. (c) Minus log10 (P-values) from PDT and FBAT for the vitiligo phenotype for the 304 SNPs genotyped across the chromosome
9 linkage region in these same 51 families. (d) Minus log10 (P-values) from PDT and FBAT for the expanded autoimmune disease phenotype for the
304 SNPs genotyped across the chromosome 9 linkage region in these 51 families. In each panel, blue circles indicate PDT P-values and red circles
indicate FBAT P-values. The dashed line represents minus log10 (0.05).
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case–pseudocontrol data set (Cordell and Clayton, 2002;
Cordell et al., 2004a) of the five SNPs derived from the
combined 114 families, using a three-stage interaction testing
framework (Millstein et al., 2006). Analyses were restricted to
two- and three-way interactions to avoid over-fitting the data,
and tests at higher stage levels were conditional on effects
that were already declared significant at lower stage levels to
avoid multiple tests of the same effect. The significance
threshold for an overall type 1 error rate of 0.05 was
determined by the Bonferroni correction based on the
number of stages and the number of tests within each stage.
As in our previous report of disease associations of NLRP1
variants in these families (Jin et al., 2007), P-values for
rs6502867 and rs4790797 met the significance threshold
(Po0.0033) in stage 1 interaction testing framework analyses
of both the vitiligo phenotype (Table 5, P¼ 0.0022 and
P¼0.0003, respectively) and the expanded autoimmune
disease phenotype (Table 6, P¼0.0005 and P¼0.0001,
respectively). Consistent with the results of univariate CLRA
(Tables 1 and 3), P-values for chromosome 7q SNP rs734930
and chromosome 9 SNP rs4744411 met the significance
threshold in stage 1 interaction testing framework analyses
(Po0.0033) of the vitiligo phenotype (Table 5, P¼0.0015
and P¼0.0011, respectively), and the P-value for chromo-
some 9 SNP rs4744411 on the expanded autoimmune
disease phenotype was very close to significant (Table 6,
P¼0.0036). Although P-values for the independent effect of
chromosome 7p SNP rs6960920 were not significant for
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Figure 2. LD patterns among the chromosome 7 and 9 linkage region SNPs. Pairwise r2 values for LD (22) (darker boxes indicate stronger LD) are shown for
the 17 SNPs from the chromosome 7 linkage region (a) and the 8 SNPs from the chromosome 9 linkage region (b) selected for replication analysis for the
vitiligo phenotype and the expanded autoimmune disease phenotype in 63 multiplex families with generalized vitiligo and other autoimmune diseases (series 2).
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either phenotype (P¼0.0141 for vitiligo, P¼0.1012 for the
expanded autoimmune disease phenotype), there was sugges-
tive evidence of a two-way interaction between rs6960920 and
NLRP1 SNP rs6502867 (Table 5, P¼0.0019; nominal sig-
nificance threshold P¼ 0.0017), as well as a significant three-
way interaction between chromosome 7 SNPs rs6960920 and
rs734930 and NLRP1 SNP rs6502867 (Table 5, P¼ 0.0009) for
the vitiligo phenotype, and a significant three-way interaction
between chromosome 7p SNP rs6960920, chromosome 9
SNP rs4744411, and NLRP1 SNP rs6502867 for both vitiligo
(Table 5, P¼ 0.0012) and the expanded autoimmune disease
phenotype (Table 6, P¼ 0.0006).
DISCUSSION
We have carried out a high-density SNP association study
across regions of genetic linkage we previously detected on
chromosome 7 and 9 for generalized vitiligo, an autoimmune
disease of skin depigmentation. The family-based nature of
the study makes the results robust against false-positive
associations from cryptic population stratification. The
linkage results suggested that loci in these regions might
contribute to both generalized vitiligo and to a broader
autoimmunity phenotype.
Three signals, tagged by SNPs rs6960920 in 7p13,
rs734930 in 7q11, and rs4744411 in 9q22, were significantly
associated with generalized vitiligo as well as with a broader
autoimmunity phenotype that included vitiligo and other
autoimmune diseases commonly associated with vitiligo.
These three SNPs also showed significant interactions with
NLRP1 SNP rs6502867, which we previously showed to be
associated with vitiligo and other autoimmune diseases in
these families (Jin et al., 2007). Both chromosome 7 signals
yielded better P-values for the vitiligo phenotype than for the
expanded autoimmunity phenotype, whereas the chromo-
some 9 signal yielded generally better P-values for the
expanded autoimmunity phenotype. Nevertheless, a three-
way interaction model that included SNP rs6960920 (7p13),
rs4744411 (9q22), and rs6502867 (NLRP1) yielded a better
P-value for the autoimmunity phenotype, suggesting that
the 7p13 signal may contribute to broader autoimmune
susceptibility.
The rs6960920–rs2331071–rs2240100 SNP cluster is
located in a region of chromosome 7p13 that contains two
genes, CAMK2B and NUDCD3. This SNP cluster is located
50 to CAMK2B and 5 kb 30 to NUDCD3, and rs2331071 and
rs2240100 are located within NUDCD3. CAMK2B encodes
an apparent member of the serine/threonine protein kinase
and Ca(2þ)/calmodulin-dependent protein kinase subfami-
lies that has an essential role in PAF-induced macrophage
priming; CAMK2B is thus a tenable biological candidate gene
Table 1. P-values for allelic association of chromosome 7 variants with generalized vitiligo and an expanded
autoimmune disease phenotype
51 Family P-value 63 Family P-value2 Combined 114 family P-value
Variant/allele Position (bp)1 PDT3 FBAT4 PDT3 FBAT4 PDT3 FBAT4 CLRA5 HRAF6 OR (95% CI)7
Vitiligo
rs6960920/G 44,382,597 0.0036 0.0283 0.0117 0.0378 0.00038 0.0066 0.0150 0.558 1.71 (1.11–2.63)
rs2331071/G 44,396,776 0.0179 0.0349 0.0112 0.0539 0.00109 0.0159 0.0124 0.592 1.71 (1.12–2.62)
rs2240100/A 44,433,254 0.0061 0.0444 0.0222 0.0731 0.00129 0.0198 0.0150 0.555 1.71 (1.11–2.63)
rs734930/G 69,658,096 0.0329 0.0045 0.0205 0.0481 0.00329 0.00169 0.00349 0.503 1.85 (1.22–3.76)
Expanded autoimmune disease phenotype10
rs6960920/G 44,382,597 0.0102 0.0310 0.0261 0.1550 0.00179 0.0337 0.0704 0.558 1.41 (0.97–2.05)
rs2331071/G 44,396,776 0.0294 0.0493 0.0121 0.1388 0.0041 0.0519 0.0826 0.592 1.39 (0.96–2.01)
rs2240100/A 44,433,254 0.0171 0.0485 0.0497 0.2572 0.0057 0.0910 0.1147 0.555 1.35 (0.93–1.95)
rs734930/G 69,658,096 0.0360 0.0192 0.0195 0.1416 0.00339 0.0132 0.0129 0.503 1.55 (1.10–2.20)
CI, confidence interval; CLRA, conditional logistic regression analysis; FBAT, family-based association test; OR, odds ratio; PDT, pedigree
disequilibrium test.
1Nucleotide positions are from National Center for Biotechnology Information (NCBI) (Build 36.3).
2One-tailed P-value if the family series 2 showed association with the same high-risk allele as in the family series 1.
3PDT (Martin et al., 2000).
4FBAT (Horvath et al., 2004).
5CLRA of the case–pseudocontrol data set (Cordell and Clayton, 2002) derived from the combined 114 families, in which an additive genotypic effect for the
high-risk allele of each marker was assumed. We also used logistic-regression models to evaluate the mode of inheritance of risk individually associated
with rs6960920 and rs734930, which favored an additive model with no dominant or recessive effects of these markers.
6The high-risk allele frequency from the total 114 families.
7ORs were calculated from the coefficients of the regression equation.
8P-value o0.01 after the Bonferroni correction for 14 independent tests.
9P-value o0.05 after the Bonferroni correction for 14 independent tests.
10Expanded autoimmune disease phenotype, in which individuals with any of generalized vitiligo, autoimmune thyroid disease, rheumatoid arthritis,
psoriasis, adult-onset autoimmune diabetes mellitus, pernicious anemia, systemic lupus erythematosus, or Addison’s disease were considered as
affected.5,6
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for generalized vitiligo. NUDCD3 encodes a protein that
functions to maintain the stability of dynein intermediate
chain, and appears as an unlikely candidate gene for
susceptibility to vitiligo and other autoimmune diseases.
SNP rs734930 is located in 7q11.2, within an intron of
AUTS2, a putative autism candidate gene of unknown
Table 2. Second locus effect tests of the chromosome 7 SNPs in a forward stepwise-regression procedure for the
generalized vitiligo and expanded autoimmune disease phenotypes
Null
model
Alternative
model P-value1
Null
model
Alternative
model P-value1
Null
model
Alternative
model P-value1
Null
model
Alternative
model P-value1
Vitiligo
A A+B 0.4607 B B+A 0.8095 — — — — — —
A A+C Not concave C C+A Not concave D D+B 0.0139 B B+D 0.0030
A A+D 0.0028 D D+A 0.0152 D D+C 0.0152 C C+D 0.0028
Expanded autoimmune disease phenotype2
A A+B 0.6435 B B+A 0.9287 — — — — — —
A A+C Not concave C C+A Not concave D D+B 0.0755 B B+D 0.0098
A A+D 0.0109 D D+A 0.0887 D D+C 0.1148 C C+D 0.0107
A, rs66960920; B, rs2331071; C, rs2240100; D, rs734930. ‘‘Not concave’’ means it is impossible to obtain a unique estimate of regression coefficients with
both variables in the model, which happens when one independent variable is a perfect linear combination of the other, as in the case of perfect LD.
1P-values from conditional logistic regression analyses.
2Expanded autoimmune disease phenotype (see Table 1).
Table 3. P-values for allelic association of the chromosome 9 variants with generalized vitiligo and an expanded
autoimmune disease phenotype
51 Family P-value 63 Family P-value2 Combined 114 family P-value
Variant/allele Position (bp)1 PDT3 FBAT4 PDT3 FBAT4 PDT3 FBAT4 CLRA5 HRAF6 OR (95% CI)7
Vitiligo
rs4744369/T 96,515,217 0.0335 0.0090 0.1559 0.0543 0.0236 0.00238 0.0045 0.411 1.84 (1.21–2.81)
rs2584806/G 96,569,099 0.0229 0.0065 0.1407 0.0484 0.0158 0.00158 0.00288 0.400 1.94 (1.26–3.01)
rs391784/A 96,615,448 0.0229 0.0065 0.0941 0.0314 0.0104 0.00108 0.00178 0.394 2.03 (1.31–3.16)
rs4744411/A 96,728,866 0.0439 0.0072 0.1462 0.0541 0.0307 0.00188 0.00108 0.417 2.03 (1.33–3.10)
Expanded autoimmune disease phenotype9
rs4744369/T 96,515,217 0.0198 0.0133 0.0165 0.0350 0.0177 0.00228 0.0038 0.411 1.89 (1.23–2.91)
rs2584806/G 96,569,099 0.0198 0.0133 0.0279 0.0578 0.0258 0.00338 0.00358 0.400 1.96 (1.25–3.07)
rs391784/A 96,615,448 0.0198 0.0133 0.0185 0.0364 0.0171 0.00228 0.00208 0.394 2.04 (1.30–3.20)
rs4744411/A 96,728,866 0.0082 0.0039 0.0185 0.0278 0.0053 0.000510 0.00128 0.417 2.05 (1.33–3.16)
CI, confidence interval; CLRA, conditional logistic regression analysis; FBAT, family-based association test; OR, odds ratio; PDT, pedigree
disequilibrium test.
1Nucleotide positions are from the National NCBI Build 36.3.
2One-tailed P-value if family series 2 showed association with the same high-risk allele as in the family series 1.
3PDT (Martin et al., 2000).
4FBAT (Horvath et al., 2004).
5CLRA of the case–pseudocontrol data set (Cordell and Clayton, 2002) derived from the combined 114 families, in which an additive genotypic effect for the
high-risk allele of each marker was assumed. We also used logistic-regression models to evaluate the mode of inheritance of risk associated with rs4744411,
which favored an additive model with no dominant or recessive effect.
6The high-risk allele frequency from the total 114 families.
7ORs were calculated from the coefficients of the regression equation.
8P-value o0.05 after the Bonferroni correction for 14 independent tests.
9Expanded autoimmune disease phenotype (see Table 1).
10P-value o0.01 the after Bonferroni correction for 14 independent tests.
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Table 4. Second locus effect tests of chromosome 9 SNPs in a forward stepwise-regression procedure for the
generalized vitiligo and expanded autoimmune disease phenotypes
Null
model
Alternative
model P-value1
Null
model
Alternative
model P-value1
Null
model
Alternative
model P-value1
Null
model
Alternative
model P-value1
Vitiligo
A A+B 0.0160 B B+A 0.1170 B B+C Not concave C C+B Not concave
A A+C 0.0160 C C+A 0.1186 B B+D 0.3171 D D+B 0.9128
A A+D 0.1976 D D+A 0.7689 C C+D 0.5678 D D+C 0.5195
Expanded autoimmune disease phenotype2
A A+B 0.0638 B B+A 0.7056 B B+C Not concave C C+B Not concave
A A+C 0.0359 C C+A 0.2305 B B+D 0.2976 D D+B 0.9558
A A+D 0.2784 D D+A 0.9019 C C+D 0.4441 D D+C 0.6070
A, rs4744369; B, rs2584806; C, rs391784; D, rs4744411. ‘‘Not concave’’ means it is impossible to obtain an unique estimate of regression coefficients with
both variables in the model, which happens when one independent variable is a perfect linear combination of the other, as in the case of perfect LD.
1P-values from conditional logistic regression analyses.
2Expanded autoimmune disease phenotype (see Table 1).
Table 5. Wald tests of interactions for the generalized vitiligo phenotype using an interaction testing framework
Stage Null model Saturated model v2 d.f. Significance threshold1 P-value
1 — b1S1 6.03 1 0.0033 0.0141
1 — b2S2 10.10 1 0.0033 0.0015
1 — b3S3 10.73 1 0.0033 0.0011
1 — b4S4 9.37 1 0.0033 0.0022
1 — b5S5 13.33 1 0.0033 0.0003
2 b2S2 b1S1+b2S2+b12S1S2 7.75 2 0.0017 0.0227
2 b3S3 b1S1+b3S3+b13S1S3 7.67 2 0.0017 0.0216
2 b4S4 b1S1+b4S4+b14S1S4 12.53 2 0.0017 0.0019
2 b5S5 b1S1+b5S5+b15S1S5 8.52 2 0.0017 0.0141
2 b2S2+b3S3 b2S2+b3S3+b23S2S3 0.15 1 0.0017 0.7032
2 b2S2+b4S4 b2S2+b4S4+b24S2S4 2.10 1 0.0017 0.1474
2 b2S2+b5S5 b2S2+b5S5+b25S2S5 0.59 1 0.0017 0.4428
2 b3S3+b4S4 b3S3+b4S4+b34S3S4 6.09 1 0.0017 0.0136
2 b3S3+b5S5 b3S3+b5S5+b35S3S5 0.01 1 0.0017 0.9128
2 b4S4+b5S5 b4S4+b5S5+b45S4S5 0.01 1 0.0017 0.9269
3 b2S2+b3S3 b1S1+b2S2+b3S3+b12S1S2+b13S1S3+b23S2S3+b123S1S2S3 16.32 5 0.0017 0.0060
3 b2S2+b4S4 b1S1+b2S2+b4S4+b12S1S2+b14S1S4+b24S2S4+b124S1S2S4 20.64 5 0.0017 0.0009
3 b2S2+b5S5 b1S1+b2S2+b5S5+b12S1S2+b15S1S5+b25S2S5+b125S1S2S5 10.93 5 0.0017 0.0528
3 b3S3+b4S4 b1S1+b3S3+b4S4+b13S1S3+b14S1S4+b34S3S4+b134S1S3S4 20.16 5 0.0017 0.0012
3 b3S3+b5S5 b1S1+b3S3+b5S5+b13S1S3+b15S1S5+b35S3S5+b135S1S3S5 10.79 5 0.0017 0.0558
3 b4S4+b5S5 b1S1+b4S4+b5S5+b14S1S4+b15S1S5+b45S4S5+b145S1S4S5 16.44 5 0.0017 0.0057
3 b2S2+b3S3+b4S4 b2S2+b3S3+b4S4+b23S2S3+b24S2S4+b34S3S4+b234S2S3S4 7.94 4 0.0017 0.00938
3 b2S2+b3S3+b5S5 b2S2+b3S3+b5S5+b23S2S3+b25S2S5+b35S3S5+b235S2S3S5 6.53 4 0.0017 0.1630
3 b2S2+b4S4+b5S5 b2S2+b4S4+b5S5+b24S2S4+b25S2S5+b45S4S5+b245S2S4S5 5.12 4 0.0017 0.2757
3 b3S3+b4S4+b5S5 b3S3+b4S4+b5S5+b34S3S4+b35S3S5+b45S4S5+b345S3S4S5 6.61 4 0.0017 0.1577
1Significance threshold after the Bonferroni correction. SNPs S1, S2, S3, S4, and S5 correspond to SNPs rs6960920, rs734930, rs4744411, rs6502867, and
rs4790797, respectively, and the effects of which were assumed to be log-additive. The d.f. value for a test is the difference in the number of parameters
between the null and saturated models.
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function; and SNP rs4744411 is located in chromosome
9q22, within an intron of C9orf3, a predicted gene of
unknown function. Further studies of these to identify the
specific causal genes and causal disease susceptibility
variants will elucidate new biological pathways that medi-
ate susceptibility to generalized vitiligo and associated
autoimmune diseases, facilitating the development of new
approaches to the treatment or prevention of these disorders.
MATERIALS AND METHODS
Subjects
Study subjects included 656 individuals from 114 Caucasian
extended families with generalized vitiligo and additional auto-
immune diseases from the United States and the United Kingdom.
Families were selected based on the joint criteria of multiple family
members affected with generalized vitiligo, and at least one family
member affected with at least one of the other autoimmune diseases
that are epidemiologically associated with generalized vitiligo
(autoimmune thyroid disease, rheumatoid arthritis, adult-onset
autoimmune diabetes mellitus, psoriasis, pernicious anemia,
systemic lupus erythematosus, and Addison’s disease) (Alkhateeb
et al., 2003; Laberge et al., 2005). We studied two family series.
Series 1 included 51 extended families (333 individuals) that we had
previously used to map a vitiligo-autoimmune disease locus to
chromosome 1, 7, 8 and 17 (Spritz et al., 2004), and series 2
included 63 similar independent families (323 individuals). All
families from series 1, and about half from series 2, are presented in
Laberge et al., 2005.
All available relevant affected and unaffected family members
completed a detailed questionnaire providing clinical history of
about 50 autoimmune, autoinflammatory, and immune-related
diseases. All data were reviewed by the study investigators, and
most family members (affected and unaffected) were personally
examined by one of the study staff. Clinical details of the 114 study
families, including co-morbid autoimmune diseases, have been
described previously (Jin et al., 2007). This study was approved by
Table 6. Wald tests of interactions for the expanded autoimmune disease phenotype using an interaction testing
framework
Stage Null model Saturated model v2 d.f. Significance threshold1 P-value
1 — b1S1 2.69 1 0.0033 0.1012
1 — b2S2 5.87 1 0.0033 0.0154
1 — b3S3 8.49 1 0.0033 0.0036
1 — b4S4 12.11 1 0.0033 0.0005
1 — b5S5 14.95 1 0.0033 0.0001
2 — b1S1+b2S2+b12S1S2 6.50 3 0.0017 0.0896
2 — b1S1+b3S3+b13S1S3 13.28 3 0.0017 0.0041
2 b4S4 b1S1+b4S4+b14S1S4 7.00 2 0.0017 0.032
2 b5S5 b1S1+b5S5+b15S1S5 3.00 2 0.0017 0.2231
2 — b2S2+b3S3+b23S2S3 12.66 3 0.0017 0.0054
2 b4S4 b2S2+b4S4+b24S2S4 6.54 2 0.0017 0.0380
2 b5S5 b2S2+b5S5+b25S2S5 6.10 2 0.0017 0.0474
2 b4S4 b3S3+b4S4+b34S3S4 12.01 2 0.0017 0.0025
2 b5S5 b3S3+b5S5+b35S3S5 8.86 2 0.0017 0.0119
2 b4S4+b5S5 b4S4+b5S5+b45S4S5 0.11 1 0.0017 0.7449
3 — b1S1+b2S2+b3S3+b12S1S2+b13S1S3+b23S2S3+b123S1S2S3 22.16 7 0.0017 0.0024
3 b4S4 b1S1+b2S2+b4S4+b12S1S2+b14S1S4+b24S2S4+b124S1S2S4 12.98 6 0.0017 0.0433
3 b5S5 b1S1+b2S2+b5S5+b12S1S2+b15S1S5+b25S2S5+b125S1S2S5 7.89 6 0.0017 0.2463
3 b4S4 b1S1+b3S3+b4S4+b13S1S3+b14S1S4+b34S3S4+b134S1S3S4 23.68 6 0.0017 0.0006
3 b5S5 b1S1+b3S3+b5S5+b13S1S3+b15S1S5+b35S3S5+b135S1S3S5 20.38 6 0.0017 0.0024
3 b4S4+b5S5 b1S1+b4S4+b5S5+b14S1S4+b15S1S5+b45S4S5+b145S1S4S5 8.37 5 0.0017 0.1370
3 b4S4 b2S2+b3S3+b4S4+b23S2S3+b24S2S4+b34S3S4+b234S2S3S4 20.49 6 0.0017 0.0023
3 b5S5 b2S2+b3S3+b5S5+b23S2S3+b25S2S5+b35S3S5+b235S2S3S5 17.56 6 0.0017 0.0074
3 b4S4+b5S5 b2S2+b4S4+b5S5+b24S2S4+b25S2S5+b45S4S5+b245S2S4S5 7.75 5 0.0017 0.1706
3 b4S4+b5S5 b3S3+b4S4+b5S5+b34S3S4+b35S3S5+b45S4S5+b345S3S4S5 13.50 5 0.0017 0.0191
1Significance threshold after Bonferroni correction. SNPs S1, S2, S3, S4, and S5 correspond to SNPs rs6960920, rs734930, rs4744411, rs6502867, and
rs4790797, respectively, and the effects of which were assumed to be log-additive. The d.f. value for a test is the difference in the number of parameters
between the null and saturated models.
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the Colorado Multiple Institutional Review Board (COMIRB) and the
South Thames Regional Multicentre Research Ethics Committee
(MREC), and the Declaration of Helsinki protocols were followed.
Written informed consent was obtained from all study participants.
Genotyping
DNAwas prepared from peripheral blood or saliva using the Puregene
Genomic DNA Purification Kit (Gentra Systems, Minneapolis, MN)
or Oragene Collection Kit (Oragene; DNA Genotek, Ottawa,
Ontario, Canada) respectively. We used the Illumina genotyping
service (Illumina, San Diego, CA) to genotype the same 51 families
(series 1) we previously used for genetic linkage analysis (Spritz
et al., 2004), assaying 867 SNPs spanning the chromosome 7
linkage region (47 kb average spacing) and 304 SNPs spanning the
chromosome 9 linkage region (42 kb average spacing). We next
carried out a replication study in an independent series of 63 families
(series 2) collected using the same criteria as series 1, genotyping the
17 SNPs from the chromosome 7 linkage region and the 8 SNPs from
the chromosome 9 linkage region that yielded nominally significant
association (Po0.05) by both PDT (Martin et al., 2000) and FBAT
(Horvath et al., 2004) in series 1. Genotyping of the total 25 SNPs in
series 2 was performed using the ABI Prism SNaPshot Multiplex kit
on an ABI 3130XL DNA analyzer (Applied Biosystems, Foster City,
CA) with HPLC-purified oligonucleotides (Operon, Huntsville, AL).
To compare genotyping results obtained using the two platforms, we
used the ABI system to re-genotype nine SNPs in the 333 individuals
of series 1 and obtained a concordance rate of 99.8%.
Statistical analyses
Preliminary analyses. We assessed the inheritance of each marker
in all families using PedCheck (O’Connell and Weeks, 1998) to test
for inconsistencies owing to non-paternity, new mutations, or other
errors.
Genetic linkage analysis. Analyses of our previous microsatellite
data (Spritz et al., 2004) were carried out by applying the improved
error-checking routine implemented in Merlin 1.0.0 (Abecasis et al.,
2002) and then using Allegro 1.2c software (Gudbjartsson et al.,
2000) to calculate LOD scores using an exponential model under the
Spairs allele-sharing statistic.
Hardy–Weinberg equilibrium, LD, and disease association
analyses. Testing for the Hardy–Weinberg equilibrium in founders
and persons not in the line of descent, such as spouses, in all 114
families, and calculation of LD between NLRP1 region markers, was
carried out using Haploview (Barrett et al., 2005) version 4.1.
Calculation of the association of each marker with generalized
vitiligo or with an expanded autoimmune phenotype that included
any of generalized vitiligo, autoimmune thyroid disease, rheumatoid
arthritis, adult-onset autoimmune diabetes mellitus, psoriasis,
pernicious anemia, systemic lupus erythematosus, or Addison’s
disease was carried out using PDT (Martin et al., 2000) and FBAT
(Horvath et al., 2004). Haplotype-based transmission-disequilibrium
statistics were calculated using FBAT.
To distinguish independent associations from secondary associa-
tions owing to LD, we applied CLRA (Cordell and Clayton, 2002) to
the case–pseudocontrol data set derived from the combined 114
families. To allow for correlation between multiple affected
individuals within a single pedigree, we clustered cases and
matched pseudocontrols by pedigree and used robust the Huber–-
White variance estimators to assess the significance of each
association (Cordell, 2004b). We assumed an additive genotypic
effect for the high-risk allele of each locus. ORs were estimated using
the coefficients from the regression equations for individual markers.
As a test of the independent effect of a given locus conditioned on
the effect of another locus, we compared the fit of a model
containing both loci to a model containing only the conditioning
locus (Cordell and Clayton, 2002). To test interactions among the
chromosome 7 SNPs rs6960920 and rs734930, the chromosome 9
SNP rs4744411, and theNLRP1 SNPs rs6502867 and rs4790797, we
carried out CLRA in the combined case–pseudocontrol data set
(generated by combining the case–pseudocontrol data sets of the two
chromosome 7 SNPs, the one chromosome 9 SNP, and the two
NLRP1 SNPs derived from the combined 114 families) (Cordell and
Clayton, 2002; Cordell et al., 2004a) using a three-stage interaction
testing framework (Millstein et al., 2006) in order to test individual
effects of signals represented by the five SNPs (stage 1), together
with two-way interactions (stage 2) and with three-way interactions
(stage 3). Analyses were carried out using STATA (http://www.
stata.com), using the ‘‘geneassoc’’ routine (http://www-gene.cimr.
cam.ac.uk/clayton/software/stata), and we assessed significance
using a Wald test.
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